Dexcom (Nasdaq:DXCM) today unveiled its upcoming Super Bowl commercial that announces the U.S. launch of its next-generation Dexcom G7 CGM. The ad, set to run during the second quarter of Super Bowl LVII on Feb. 12, features musician, actor and philanthropist Nick Jonas. Jonas lives with type 1 diabetes and uses Dexcom’s continuous glucose monitors […]
Diabetes
Glooko picks up security certification for diabetes patient management platform
Glooko announced today that it received ISO 27001 certification for its data management and remote patient monitoring platforms. Palo Alto, California-based Glooko develops remote patient monitoring and chronic care management products. These include data management technologies for insulin delivery devices. ISO 27001, an international compliance framework, serves as the international security standard for protecting customer […]
Tidepool Loop automated insulin delivery system wins FDA clearance
Tidepool announced recently that the FDA cleared its Tidepool Loop, a “do-it-yourself,” (DIY) automated insulin delivery (AID) system. Palo Alto, California-based Tidepool is a non-profit diabetes data management group. It created the hybrid, closed-loop AID app for compatibility with multiple insulin pumps and continuous glucose monitors. The company announced collaborations in the past that include […]
Know Labs inks partnerships to accelerate progress toward FDA clearance for glucose monitor
Know Labs (NYSE:KNW) announced that it entered into a series of strategic partnerships as it looks to move toward a major regulatory nod. Seattle-based Know Labs develops the Bio-RFID technology. It uses spectroscopy to direct electromagnetic energy through a substance or material to capture a unique molecular signature. This technology integrates into wearable, mobile or bench-top […]
How Embecta started strong and what’s ahead for the BD diabetes spinoff
Ten months after spinning off from BD, Embecta CEO Dev Kurdikar lays out what the future holds for the diabetes technology company. When Embecta became a standalone company in April 2022, CFO Jake Elguicze said he felt it was “uniquely positioned.” As a pure-play diabetes technology developer, its beginning phase hardly mirrors a normal startup. […]
Fractyl Health ‘encouraged’ by results from diabetes reversal study
Fractyl Health announced today that six-month data from a study of its diabetes reversal tech demonstrated improvements in glucose control. Interim data came from the human clinical experience in Fractyl’s Revita-T2Di long-term, open-label cohort. Revita, a procedure that remodels the duodenal lining via hydrothermal ablation, has FDA breakthrough device designation. The FDA approved an investigational […]
Study backs digital diabetes program from Vida Health
Vida Health announced that a study of its digital health diabetes management program demonstrated improvements in multiple metrics. San Francisco-based Vida Health published an article in JMIR Formative Research. Results from 1,128 participants demonstrated dramatic improvements in glycemic control. It also highlighted an important relationship between the improved management of depression and diabetes. Participants enrolled in […]
Glucose monitor maker Know Labs names new CEO, makes other executive changes
Know Labs (NYSE:KNW) announced that it named Ron Erickson as CEO as the company makes a handful of changes at the top. The Seattle-based non-invasive glucose monitor maker’s board unanimously named Erickson, its founder and chair, as CEO. Former CEO Phil Bosua stepped down as an executive officer of the company and board member. Know […]
Nemaura Medical garners U.S.-based purchase order for glucose sensors
Nemaura Medical (Nasdaq:NMRD) announced that it received a purchase order for 5,000 proBEAT glucose sensor subscriptions. HealthFleet, a U.S.-based telehealth provider, made the purchase order. It consists of 75,000 proBEAT glucose sensors over an initial five-month period. Nemaura values the deal at $500,000 in revenue, while HealthFleet possesses the option to increase volumes based on […]
Embecta opens new global headquarters in New Jersey
Embecta (Nasdaq:EMBC) announced today that it held a grand opening ceremony at its new global headquarters in New Jersey. The BD Diabetes business spinoff opened its new headquarters at 300 Kimball Drive, Suite 300, in Parsippany, New Jersey. The site houses members of the Embecta leadership team, global support functions and North American commercial organization. […]